0NES.LSE Oriola Oyj Series B
- Market cap
- EUR 171M
- P/E
- 6.7x
- P/B
- -
- ROE
- -1.9%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.
Is 0NES.LSE undervalued?
Graham numberThe Graham number of Oriola Oyj Series B cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Oriola Oyj Series B fundamental analysis
No fundamental analysis for Oriola Oyj Series B yet.
Oriola Oyj Series B stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Oriola Oyj Series B
Oriola Oyj engages in the wholesale of pharmaceuticals and health products in Sweden, Finland, and internationally. The company distributes vitamins, food and food supplements, sports nutrients, wound care, beauty, and makeup related products; vaccines; and over-the-counter products. In addition, it provides pharmaceutical logistics; special licensed medicine importing, dose dispensing, and research pharmacy services; and commercial data, clinical trial, regulatory affairs a…
Full company profileOriola Oyj Series B financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 3 quarters up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Oriola Oyj Series B annual financial statements
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 1.59B | 1.53B | 1.55B | 1.72B | 1.80B | 1.45B | 1.54B | 1.50B | 1.68B | 1.91B | 206M |
| Gross Profit | 142M | 139M | 127M | 111M | 115M | 36.4M | 31.4M | 72.6M | 74.1M | 67.9M | 6.80M |
| Operating Income | 64.0M | 52.9M | 37.1M | 28.7M | 33.5M | 10.1M | 4.20M | 13.5M | 11.6M | 7.30M | 7.33M |
| EBITDA | 89.9M | 64.5M | 48.6M | 57.1M | 62.0M | 30.3M | 39.3M | -58.4M | 26.7M | 25.0M | 20.3M |
| Net Income | 42.8M | 26.6M | 10.8M | 8.00M | 11.3M | 11.3M | 27.0M | -20.7M | -20.1M | -27.2M | -1.73M |
| EPS | 0.24 | 0.15 | 0.06 | 0.04 | 0.06 | 0.06 | 0.15 | -0.11 | -0.11 | -0.15 | -0.01 |
| Balance Sheet | |||||||||||
| Total Assets | 925M | 922M | 924M | 1.03B | 1.17B | 1.09B | 961M | 935M | 876M | 946M | 772M |
| Total Liabilities | 720M | 725M | 746M | 873M | 996M | 876M | 735M | 763M | 742M | 845M | 680M |
| Shareholders' Equity | 205M | 198M | 178M | 157M | 170M | 217M | 226M | 171M | 133M | 101M | 91.9M |
| Cash & Short-term Investments | 60.8M | 17.0M | 65.8M | 70.8M | 168M | 109M | 161M | 138M | 114M | 152M | 109M |
| Total Debt | 133M | 127M | 117M | 177M | 296M | 210M | 137M | 118M | 78.8M | 78.3M | 71.2M |
| Cash Flow | |||||||||||
| Operating Cash Flow | 40.2M | 23.7M | 103M | 84.4M | 58.3M | 40.0M | 77.9M | 9.60M | 38.7M | 60.0M | -38.5M |
| Capital Expenditure | 35.8M | 40.2M | 20.8M | 21.2M | 27.1M | 23.4M | 8.50M | 3.60M | 2.80M | 3.30M | 11.3M |
| Free Cash Flow | 4.40M | -16.5M | 82.0M | 63.2M | 31.2M | 16.6M | 69.4M | 6.00M | 35.9M | 56.7M | -49.9M |
| Ratios | |||||||||||
| ROE | 20.9% | 13.5% | 6.1% | 5.1% | 6.7% | 5.2% | 12.0% | -12.1% | -15.1% | -27.0% | -1.9% |
| ROA | 4.6% | 2.9% | 1.2% | 0.8% | 1.0% | 1.0% | 2.8% | -2.2% | -2.3% | -2.9% | -0.2% |
| Net Profit Margin | 2.7% | 1.7% | 0.7% | 0.5% | 0.6% | 0.8% | 1.8% | -1.4% | -1.2% | -1.4% | -0.8% |
| Debt to Equity | 0.65x | 0.64x | 0.66x | 1.13x | 1.74x | 0.97x | 0.61x | 0.69x | 0.59x | 0.78x | 0.77x |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Oriola Oyj Series B dividends
- Dividend yield
- -
- Forward dividend
- -
- Payout ratio
- -
- Ex-dividend date
- -
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2025 | 12.7M | 0.07 | - |
| 2024 | EUR 12.7M | 0.07 | - |
| 2023 | EUR 10.9M | 0.06 | - |
| 2022 | EUR 7.30M | 0.04 | 27.0% |
| 2021 | EUR 5.40M | 0.03 | 47.8% |
| 2020 | EUR 16.3M | 0.09 | 144.2% |
| 2019 | EUR 16.3M | 0.09 | 203.8% |
| 2018 | EUR 16.3M | 0.09 | 150.9% |
| 2017 | EUR 25.4M | 0.14 | 95.5% |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Last stock split: 758:715 on Feb 11, 2015.
Who owns Oriola Oyj Series B
- Insiders 32.74%
- Institutions 12.62%
- Public & others 54.65%
- Shares outstanding 181M
- Free float 138M
Oriola Oyj Series B company profile
- Company name
- Oriola Oyj Series B
- Ticker
- 0NES.LSE
- ISIN
- FI0009014351
- Exchange
- London Exchange
- Sector
- Healthcare
- Industry
- Oil, Gas & Consumable Fuels
- Employees
- 800
- Fiscal year end
- December
- Address
- Orionintie 5, Espoo, Finland, 02200
- Phone
- 358 1042 999
- Website
- oriola.com
About Oriola Oyj Series B
Oriola Oyj engages in the wholesale of pharmaceuticals and health products in Sweden, Finland, and internationally. The company distributes vitamins, food and food supplements, sports nutrients, wound care, beauty, and makeup related products; vaccines; and over-the-counter products. In addition, it provides pharmaceutical logistics; special licensed medicine importing, dose dispensing, and research pharmacy services; and commercial data, clinical trial, regulatory affairs and quality, medical and scientific affairs, market access and tenders, real world evidence, sales support, medical translation, pharmacovigilance and medical information, and patient support services. Further, the company provides advisory services. It serves pharmaceutical companies, pharmacies, veterinarians, hospitals, healthcare providers, special stores, retailers, and e-commerce companies. The company was founded in 1907 and is headquartered in Espoo, Finland.
Oriola Oyj Series B management
10- Ms. Katarina Gabrielson M.Sc.President & CEO · born 1969
- Mr. Mats Danielsson M.Sc.EconChief Financial Officer · born 1969
- Ms. Tua Stenius-ÖrnhjelmManager of Investor Relations & Sustainability · born 1975
- Mr. Petter Sandstrom L.L.M.General Counsel & Secretary to the Board · born 1976
- Mr. Mikael Wegmüller M.Sc. (Econ.)Vice President of Communications & Sustainability · born 1966
- Mr. Stig Tornell B.Sc (Econ.)Executive VP of Sales · born 1967
- Ms. Maria Lundell M.A.Chief People Officer · born 1966
- Mr. Mikael Nurmi M.Sc.Chief Digital Officer · born 1967
- Ms. Katja Lundell M.Sc.Executive Vice President of Advisory Services · born 1974
- Ms. Satu Nylén M.Sc.Executive Vice President of Services & Products · born 1965